Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed fallopian tube cancer, Muellerian mixed tumor, endometrial cancer, uterine sarcoma, ovarian cancer with sarcoma parts, or cervical cancer No ovarian epithelial cancer PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR Karnofsky 70-100% Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin greater than 10.0 g/dL Hepatic: Bilirubin no greater than 1.25 times upper limit of normal Renal: Glomerular filtration rate at least 60 mL/min Cardiovascular: No atrial or ventricular arrhythmias No congestive heart failure even if stabilized on medication No New York Heart Association class III or IV heart disease No myocardial infarction within the past 6 months Other: No pre-existing sensory or motor neuropathy grade 2 or greater No active infection No other serious medical condition that would preclude study Not pregnant Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy Chemotherapy: No more than 1 prior chemotherapy regimen for the malignancy No other concurrent chemotherapy Endocrine therapy: Prior hormonal therapy within the past 10 days allowed No concurrent hormonal therapy Radiotherapy: At least 6 weeks since prior radiotherapy to no more than 25% of bone marrow Surgery: Not specified Other: At least 30 days since prior experimental agents No other concurrent therapies that would preclude study No concurrent participation in another study